A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is an open label Phase 1a/1b study in patients who have advanced solid cancer tumours.
Patients will receive MTL-CEBPA (an experimental drug) in combination with pembrolizumab (a
drug which has been given approval for use for some tumour types).
The Phase 1a dose escalation part of the study is designed to establish which doses of
MTL-CEBPA are safe and well-tolerated when combined with the standard dose of pembrolizumab.
Patients recruited to this part of the study will be those whose cancer progressed on
standard treatment(s) or for whom no treatments are available.
Phase 1b the dose expansion part of the study will further explore how safe and
well-tolerated these two drugs are when combined and will assess if the combination of drugs
could potentially reduce the size of tumours. Participants in this part of the study will
receive the experimental drug (MTL-CEBPA) at a dose which is considered safe and
well-tolerated based on data from the first part of the study (Phase 1a). Participants will
remain in the study taking study drugs until either death, or they choose to withdraw from
the study.